217 related articles for article (PubMed ID: 36076991)
21. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
Roffman DS
J Pharm Pract; 2016 Jun; 29(3):239-49. PubMed ID: 25660584
[TBL] [Abstract][Full Text] [Related]
22. ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis.
Orban M; Limbourg T; Neumann FJ; Ferenc M; Olbrich HG; Richardt G; Hennersdorf M; Empen K; Fuernau G; Desch S; Eitel I; Hambrecht R; Pöss J; Schneider S; Schuler G; Werdan K; Zeymer U; Thiele H; Hausleiter J
EuroIntervention; 2016 Dec; 12(11):e1395-e1403. PubMed ID: 26690314
[TBL] [Abstract][Full Text] [Related]
23. Monotherapy with a P2Y
Chiarito M; Sanz-Sánchez J; Cannata F; Cao D; Sturla M; Panico C; Godino C; Regazzoli D; Reimers B; De Caterina R; Condorelli G; Ferrante G; Stefanini GG
Lancet; 2020 May; 395(10235):1487-1495. PubMed ID: 32386592
[TBL] [Abstract][Full Text] [Related]
24. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
[TBL] [Abstract][Full Text] [Related]
25. [Myocardial infarction: Role of new antiplatelet agents].
Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
[TBL] [Abstract][Full Text] [Related]
26. Reversal of the platelet inhibitory effect of the P2Y
Schoener L; Jellinghaus S; Richter B; Pfluecke C; Ende G; Christoph M; Quick S; Loehn T; Speiser U; Poitz DM; Mierke J; Strasser RH; Ibrahim K
Clin Res Cardiol; 2017 Nov; 106(11):868-874. PubMed ID: 28653184
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
Teng R
Clin Pharmacokinet; 2012 May; 51(5):305-18. PubMed ID: 22489610
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials.
Roule V; Agueznai M; Sabatier R; Blanchart K; Lemaître A; Ardouin P; Collet JP; Milliez P; Montalescot G; Beygui F
Platelets; 2017 Mar; 28(2):174-181. PubMed ID: 27657930
[TBL] [Abstract][Full Text] [Related]
29. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
Dayoub EJ; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Giri J; Groeneveld PW
JAMA Intern Med; 2018 Jul; 178(7):943-950. PubMed ID: 29799992
[TBL] [Abstract][Full Text] [Related]
30. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
31. Antiplatelet treatments: recent evidence from randomized controlled trials.
Vogel B; Baber U
Curr Opin Cardiol; 2017 Jul; 32(4):356-362. PubMed ID: 28463894
[TBL] [Abstract][Full Text] [Related]
32. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent.
Steiner JB; Wu Z; Ren J
Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):398-403. PubMed ID: 23590223
[TBL] [Abstract][Full Text] [Related]
34. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
[TBL] [Abstract][Full Text] [Related]
35. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Clemmensen P; Dridi NP; Holmvang L
Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
[TBL] [Abstract][Full Text] [Related]
36. Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
Desai RJ; Spoendlin J; Mogun H; Gagne JJ
Pharmacotherapy; 2017 Oct; 37(10):1322-1327. PubMed ID: 28833345
[TBL] [Abstract][Full Text] [Related]
37. Monitoring Antiplatelet Therapy.
Orme R; Judge HM; Storey RF
Semin Thromb Hemost; 2017 Apr; 43(3):311-319. PubMed ID: 28264200
[TBL] [Abstract][Full Text] [Related]
38. [Antiplatelet agents and transfusion].
Gaussem P; Martin AC; Belleville-Rolland T; Helley D; Bachelot-Loza C; Godier A
Transfus Clin Biol; 2017 Sep; 24(3):160-165. PubMed ID: 28645644
[TBL] [Abstract][Full Text] [Related]
39. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
40. Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy.
Nagalla S; Sarode R
Transfus Med Rev; 2019 Apr; 33(2):92-97. PubMed ID: 30814031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
